These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29741737)

  • 21. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
    Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
    Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
    Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
    J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
    J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.
    Lee MD; Jain R; Galbraith K; Chen A; Lieberman E; Patel SH; Placantonakis DG; Zagzag D; Barbaro M; Guillermo Prieto Eibl MDP; Golfinos JG; Orringer DA; Snuderl M
    Clin Cancer Res; 2024 Aug; 30(16):3512-3519. PubMed ID: 38829583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
    Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
    Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IRX1 is a novel gene, overexpressed in high-grade IDH-mutant astrocytomas.
    Sugur HS; Rao S; Sravya P; Athul Menon K; Arivazhagan A; Mehta B; Santosh V
    Pathol Res Pract; 2023 May; 245():154464. PubMed ID: 37116364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas.
    Ahmeti H; Kiese D; Freitag-Wolf S; Kalab M; Röcken C; Jansen O; Mehdorn MH; Synowitz M
    J Neurooncol; 2024 Sep; 169(2):423-435. PubMed ID: 38909340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
    Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
    Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    Zschernack V; Thomas C; Schaub C; Kristiansen G; Waha A; Goschzik T; Herrlinger U; Pietsch T
    J Neuropathol Exp Neurol; 2024 Oct; 83(10):887-889. PubMed ID: 38874462
    [No Abstract]   [Full Text] [Related]  

  • 34. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
    Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
    J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels.
    Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM
    NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infratentorial IDH-mutant astrocytoma is a distinct subtype.
    Banan R; Stichel D; Bleck A; Hong B; Lehmann U; Suwala A; Reinhardt A; Schrimpf D; Buslei R; Stadelmann C; Ehlert K; Prinz M; Acker T; Schittenhelm J; Kaul D; Schweizer L; Capper D; Harter PN; Etminan N; Jones DTW; Pfister SM; Herold-Mende C; Wick W; Sahm F; von Deimling A; Hartmann C; Reuss DE
    Acta Neuropathol; 2020 Oct; 140(4):569-581. PubMed ID: 32776277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
    J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
    Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.